Sapacitabine: Interim Phase III data

Cyclacel said a planned interim analysis for futility by an independent DSMB after 247 deaths occurred in the open-label, international Phase III SEAMLESS trial

Read the full 249 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE